SCHEMBL10820229

SCHEMBL10820229

CCOc1ccccc1OCCNC(C)Cc1ccc(OC)c(SOON)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 8/20 0.64
ADRA1A P35348 8/20 0.64
ADRA1B P35368 8/20 0.64
ADRB2 P07550 3/20 0.64
ADRB1 P08588 1/20 0.64
HTR1A P08908 1/20 0.64
ADRA2A P08913 1/20 0.64
DRD2 P14416 1/20 0.64
ADRA2B P18089 1/20 0.64
ADRA2C P18825 1/20 0.64
HTR2A P28223 1/20 0.64
HTR7 P34969 1/20 0.64
OPRM1 P35372 1/20 0.64
DRD3 P35462 1/20 0.64
HTR2B P41595 1/20 0.64
KCNH2 Q12809 1/20 0.64
SIGMAR1 Q99720 7/20 0.48
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12284628 1.00 ADRA1D (0.64) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL12284587 0.90 ADRA1D (0.61) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL13623737 0.89 ADRA1D (0.50) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL13623722 0.89 ADRA1D (0.50) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL51245 0.87 ADRA1D (0.67) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL9548034 0.87 ADRA1D (0.67) ADRA1DADRA1AADRA1BADRB2ADRB1
Hydrochloric Acid SCHEMBL9548113 0.86 ADRA1D (0.66) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL11218388 0.84 ADRA1D (0.66) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL14018837 0.82 SIGMAR1 (0.49) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL14275116 0.82 SMN1; SMN2 (0.47) ADRA1DADRA1AADRA1BADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222452-B2 Method for producing optically active amines HAMARI CHEMICALS, LTD. (JP) 2012-07-17 US disclosed
US-8017803-B2 Process for the preparation of tamsulosin and intermediates thereof HOVIONE INTER LTD. (CH) 2011-09-13 US disclosed
US-20100160636-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES HAMARI CHEMICALS, LTD. (JP) 2010-06-24 US disclosed
US-20090234154-A1 Process for the preparation of tamsulosin and intermediates thereof HOVIONE INTER LTD. 2009-09-17 US disclosed
US-20090137844-A1 Crystallization process FERMION OY (FI) 2009-05-28 US disclosed
US-20090130180-A1 Preparation for External Use HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2009-05-21 US disclosed
US-20080262089-A1 Process for the Preparation of Tamsulosin MEDICHEM, S.A. (ES) 2008-10-23 US disclosed
US-7332621-B2 Process for preparing Tamsulosin SCINOPHARM TAIWAN KTD. (TW) 2008-02-19 US disclosed
US-7238839-B2 Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation DIVI'S LABORATORIES LIMITED (IN) 2007-07-03 US disclosed
US-20070142669-A1 reacting o-ethoxyphenoxyethanol with sulfonyl chloride; reacting the sulfonate with (R)-(-)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide by condensation to produce Tamsulosin SCINOPHARM TAIWAN LTD. 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090130180-A1 Preparation for External Use SOST, SLC46A1, CD44 ADRA1D 2499/4885ADRA1A 1371/4885ADRA1B 2574/4885
US-20090137844-A1 Crystallization process KLK5, REN, PCSK6 ADRA1D 76/4885ADRA1A 65/4885ADRA1B 75/4885
US-20080262089-A1 Process for the Preparation of Tamsulosin PTMS, TAAR5, VASP ADRA1D 176/4885ADRA1A 253/4885ADRA1B 44/4885
US-20090234154-A1 Process for the preparation of tamsulosin and intermediates thereof AVPR2, AVPR1B, TACR2 ADRA1D 31/4885ADRA1A 57/4885ADRA1B 9/4885
US-20070142669-A1 reacting o-ethoxyphenoxyethanol with sulfonyl chloride; reacting the sulfonate with (R)-(-)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide by condensation to produce Tamsulosin BPHL, REN, MME ADRA1D 69/4885ADRA1A 58/4885ADRA1B 33/4885
US-20100160636-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES INMT, HNMT, PADI3 ADRA1D 1633/4885ADRA1A 1737/4885ADRA1B 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.